blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2911666

EP2911666 - MODULATORS OF RESISTANT ANDROGEN RECEPTOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.06.2023
Database last updated on 16.11.2024
FormerThe patent has been granted
Status updated on  22.07.2022
FormerGrant of patent is intended
Status updated on  28.02.2022
FormerExamination is in progress
Status updated on  22.02.2022
FormerGrant of patent is intended
Status updated on  21.10.2021
FormerExamination is in progress
Status updated on  06.07.2018
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
Memorial Sloan-Kettering Cancer Center
Office Of Industrial Affairs
1275 York Avenue
New York, NY 10065 / US
[2015/36]
Inventor(s)01 / BALBAS, Minna D.
1233 York Avenue Apt. 19H
New York, New York 10065 / US
02 / EVANS, Michael J.
48 East End Avenue Apt. 4C
New York, New York 10028 / US
03 / SAWYERS, Charles L.
40 East 61st Street Apt. 9C
New York, New York 10065-8031 / US
04 / SHEN, Yang
5550 S. Dorchester Avenue Apt. 603
Chicago, Illinois 60637 / US
05 / HOSFIELD, David
3058 N Hoyne
Unit 2
Chicago, Illinois 60618 / US
06 / GREENE, Geoffrey L.
1910 N Burling Street
Unit A
Chicago, Illinois 60614 / US
 [2015/36]
Representative(s)Wallinger, Michael
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte Partnerschaft mbB
Zweibrückenstrasse 5-7
80331 München / DE
[2022/34]
Former [2015/36]Wallinger, Michael
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte
Zweibrückenstrasse 5-7
80331 München / DE
Application number, filing date13849577.525.10.2013
[2015/36]
WO2013US66875
Priority number, dateUS201261719117P26.10.2012         Original published format: US 201261719117 P
[2015/36]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014066799
Date:01.05.2014
Language:EN
[2014/18]
Type: A2 Application without search report 
No.:EP2911666
Date:02.09.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 01.05.2014 takes the place of the publication of the European patent application.
[2015/36]
Type: B1 Patent specification 
No.:EP2911666
Date:24.08.2022
Language:EN
[2022/34]
Search report(s)International search report - published on:US21.08.2014
(Supplementary) European search report - dispatched on:EP12.09.2016
ClassificationIPC:A61K31/4184
[2015/36]
CPC:
C07D401/04 (EP,US); C07D233/86 (EP,US); C07D235/02 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/36]
Extension statesBA04.05.2015
ME04.05.2015
TitleGerman:MODULATOREN EINES RESISTENTEN ANDROGENREZEPTORS[2015/36]
English:MODULATORS OF RESISTANT ANDROGEN RECEPTOR[2015/36]
French:MODULATEURS DU RÉCEPTEUR DES ANDROGÈNES ANDROGÉNO-RÉSISTANT[2015/36]
Entry into regional phase04.05.2015National basic fee paid 
04.05.2015Search fee paid 
04.05.2015Designation fee(s) paid 
04.05.2015Examination fee paid 
Examination procedure04.05.2015Examination requested  [2015/36]
07.04.2017Amendment by applicant (claims and/or description)
05.07.2018Despatch of a communication from the examining division (Time limit: M06)
15.01.2019Reply to a communication from the examining division
28.10.2019Despatch of a communication from the examining division (Time limit: M06)
07.05.2020Reply to a communication from the examining division
26.04.2021Despatch of a communication from the examining division (Time limit: M04)
17.08.2021Reply to a communication from the examining division
21.10.2021Communication of intention to grant the patent
22.02.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
22.02.2022Fee for grant paid
22.02.2022Fee for publishing/printing paid
09.03.2022Communication of intention to grant the patent
14.07.2022Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  05.07.2018
Opposition(s)25.05.2023No opposition filed within time limit [2023/31]
Fees paidRenewal fee
27.10.2015Renewal fee patent year 03
11.10.2016Renewal fee patent year 04
11.10.2017Renewal fee patent year 05
11.10.2018Renewal fee patent year 06
15.10.2019Renewal fee patent year 07
14.10.2020Renewal fee patent year 08
21.10.2021Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU25.10.2013
AL24.08.2022
AT24.08.2022
BG24.08.2022
CY24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
IT24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
MK24.08.2022
MT24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SI24.08.2022
SK24.08.2022
SM24.08.2022
IE25.10.2022
LU25.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
[2024/41]
Former [2024/34]HU25.10.2013
AL24.08.2022
AT24.08.2022
BG24.08.2022
CY24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
IT24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
MK24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SI24.08.2022
SK24.08.2022
SM24.08.2022
IE25.10.2022
LU25.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2024/27]HU25.10.2013
AL24.08.2022
AT24.08.2022
CY24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
IT24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
MK24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SI24.08.2022
SK24.08.2022
SM24.08.2022
IE25.10.2022
LU25.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2024/26]HU25.10.2013
AL24.08.2022
AT24.08.2022
CY24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
IT24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SI24.08.2022
SK24.08.2022
SM24.08.2022
IE25.10.2022
LU25.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2024/21]HU25.10.2013
AL24.08.2022
AT24.08.2022
CY24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SI24.08.2022
SK24.08.2022
SM24.08.2022
IE25.10.2022
LU25.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2024/18]HU25.10.2013
AL24.08.2022
AT24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SI24.08.2022
SK24.08.2022
SM24.08.2022
IE25.10.2022
LU25.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/48]AL24.08.2022
AT24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SI24.08.2022
SK24.08.2022
SM24.08.2022
IE25.10.2022
LU25.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/42]AL24.08.2022
AT24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SI24.08.2022
SK24.08.2022
SM24.08.2022
LU25.10.2022
BE31.10.2022
CH31.10.2022
LI31.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/37]AL24.08.2022
AT24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SI24.08.2022
SK24.08.2022
SM24.08.2022
LU25.10.2022
CH31.10.2022
LI31.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/35]AL24.08.2022
AT24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SK24.08.2022
SM24.08.2022
LU25.10.2022
CH31.10.2022
LI31.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/30]AL24.08.2022
AT24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SK24.08.2022
SM24.08.2022
LU25.10.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/29]AL24.08.2022
AT24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SK24.08.2022
SM24.08.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/25]AT24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
MC24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SK24.08.2022
SM24.08.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/23]AT24.08.2022
CZ24.08.2022
DK24.08.2022
EE24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SK24.08.2022
SM24.08.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/22]AT24.08.2022
CZ24.08.2022
DK24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
NL24.08.2022
PL24.08.2022
RO24.08.2022
RS24.08.2022
SE24.08.2022
SM24.08.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/21]DK24.08.2022
ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
NL24.08.2022
PL24.08.2022
RS24.08.2022
SE24.08.2022
SM24.08.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/20]ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
NL24.08.2022
PL24.08.2022
RS24.08.2022
SE24.08.2022
SM24.08.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/12]ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
NL24.08.2022
PL24.08.2022
RS24.08.2022
SE24.08.2022
NO24.11.2022
GR25.11.2022
IS24.12.2022
PT26.12.2022
Former [2023/11]ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
NL24.08.2022
PL24.08.2022
RS24.08.2022
SE24.08.2022
NO24.11.2022
GR25.11.2022
PT26.12.2022
Former [2023/10]ES24.08.2022
FI24.08.2022
HR24.08.2022
LT24.08.2022
LV24.08.2022
NL24.08.2022
RS24.08.2022
SE24.08.2022
NO24.11.2022
GR25.11.2022
PT26.12.2022
Former [2023/09]ES24.08.2022
FI24.08.2022
LT24.08.2022
LV24.08.2022
NL24.08.2022
RS24.08.2022
SE24.08.2022
NO24.11.2022
PT26.12.2022
Former [2023/08]ES24.08.2022
FI24.08.2022
LT24.08.2022
NL24.08.2022
RS24.08.2022
SE24.08.2022
NO24.11.2022
Documents cited:Search[X]WO2006124118  (UNIV CALIFORNIA [US], et al) [X] 1,2,5-13 * page 1, paragraph 1 * * pages 2, 3, paragraph 8 * * page 7; compound [RD162'] * * see in particular definition of variables R71-R73; pages 16, 17, paragraph 77 * * examples 9, 10 * * claims 17, 38 *;
 [X]WO2007127010  (UNIV CALIFORNIA [US], et al) [X] 1,2,5-13 * page 1, paragraph 1 * * page 3, paragraph 9 * * pages 3, 4; compound [NC54] * * pages 8, 9, paragraph 30 * * example 57 ** claims 6, 25 *
International search[A]US2010172975  (SAWYERS CHARLES L [US], et al);
 [A]WO2011106570  (MEDIVATION PROSTATE THERAPEUTICS INC [US], et al);
 [X]CA2806051  (IVACHTCHENKO ALEXANDRE VASILIEVICH [US], et al);
 [A]WO2012106368  (UNIV CALIFORNIA [US], et al);
 [A]  - CLEGG ET AL., "ARN-509: a novel anti-androgen for prostate cancer treatment.", CANCER RES., vol. 72, no. 6, (20120315), pages 1494 - 1503, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306502/?report=classic, (20140609), XP008166073

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-11-3948
by applicantUS5171741
 US5171749
 US5173504
 US5308608
 US5405957
 US5512675
 US5726304
 US5739116
 US5773001
 US5831088
 US5877296
 US5880145
 US5929105
 WO2006124118
    - R.W. REDMONDJ.N. GAMLIN, Photochem. Photobiol., (19990000), vol. 70, pages 391 - 475
    - C.M. RUDIN, Clin. Cancer Res., (20010000), vol. 7, pages 1214 - 1220
    - S. M. BERGE, J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19
    - R.A STAHEL et al., Lung Cancer, (20030000), vol. 41, pages S81 - S88
    - K.F. PIROLLO et al., Pharmacol. Ther., (20030000), vol. 99, pages 55 - 77
    - A.C. STEPHENSR.P. RIVERS, Curr. Opin. Mol. Ther., (20030000), vol. 5, pages 225 - 234
    - N.M. DEANC.F. BENNETT, Oncogene, (20030000), vol. 22, pages 6579 - 6588
    - N. SCHIAVONE et al., Curr. Pharm. Des., (20040000), vol. 10, pages 769 - 784
    - L. VIDAL et al., Eur. J. Cancer, (20050000), vol. 41, pages 2812 - 2818
    - T. ABOUL-FADL, Curr. Med. Chem., (20050000), vol. 12, pages 2193 - 2214
    - M.E. GLEAVEB.P. MONIA, Nat. Rev. Cancer, (20050000), vol. 5, pages 468 - 479
    - Y.S. CHO-CHUNG, Curr. Pharm. Des., (20050000), vol. 11, pages 2811 - 2823
    - E. RAYBURN et al., Lett. Drug Design & Discov., (20050000), vol. 2, pages 1 - 18
    - E.R. RAYBURN et al., Expert Opin. Emerg. Drugs, (20060000), vol. 11, pages 337 - 352
    - I. TAMMM. WAGNER, Mol. Biotechnol., (20060000), vol. 33, pages 221 - 238
    - C.A. STEIN et al., Semin. Oncol., (20050000), vol. 32, pages 563 - 573
    - S.R. FRANKEL, Semin. Oncol., (20030000), vol. 30, pages 300 - 304
    - S. GOEL et al., Clin. Cancer Res., (19980000), vol. 203, no. 9, pages 1903 - 1914
    - S.P. HENRY et al., Anticancer Drug Des., (19970000), vol. 12, pages 409 - 420
    - B.P. MONIA et al., Proc. Natl. Acad. Sci. USA, (19960000), vol. 93, pages 15481 - 15484
    - J. KURRECK, Eur. J. Biochem., (20030000), vol. 270, pages 1628 - 1644
    - Y. LEE et al., Cancer Res., (20030000), vol. 63, pages 2802 - 2811
    - B. LU et al., Cancer Res., (20040000), vol. 64, pages 2840 - 2845
    - A. RAIT et al., Ann. N. Y. Acad. Sci., (20030000), vol. 1002, pages 78 - 89
    - MCMANUSSHARP, Nature Rev. Genet., (20020000), vol. 3, page 737
    - ELBASHIR et al., Genes Dev., (20010000), vol. 15, page 188
    - O. MILHAVET et al., Pharmacol. Rev., (20030000), vol. 55, pages 629 - 648
    - F. BI et al., Curr. Gene. Ther., (20030000), vol. 3, pages 411 - 417
    - I. FRIEDRICH et al., Semin. Cancer Biol., (20040000), vol. 14, pages 223 - 230
    - M. IZQUIERDO, Cancer Gene Ther., (20050000), vol. 12, pages 217 - 227
    - P.Y. LU et al., Adv. Genet., (20050000), vol. 54, pages 117 - 142
    - G.R. DEVI, Cancer Gene Ther., (20060000), vol. 13, pages 819 - 829
    - M.A. BEHLKE, Mol. Ther., (20060000), vol. 13, pages 644 - 670
    - L.N. PUTRAL et al., Drug News Perspect., (20060000), vol. 19, pages 317 - 324
    - T.R BRUMMELKAMP et al., Science, (20020000), vol. 296, pages 550 - 553
    - M.T. HEMMAN et al., Nat. Genet., (20030000), vol. 33, pages 396 - 400
    - M. SCHERR et al., Blood, (20030000), vol. 101, pages 1566 - 1569
    - U. RITTER et al., Oligonucleotides, (20030000), vol. 13, pages 313 - 324
    - T.R. BRUMMELKAMP et al., Cancer Cell, (20020000), vol. 2, pages 243 - 247
    - G. YANG et al., J. Biol. Chem., (20040000), vol. 279, pages 4339 - 4345
    - M. VAN DE WETERING et al., EMBO Rep., (20030000), vol. 4, pages 609 - 615
    - SIGGEL et al., J. Phys. Chem., (19960000), vol. 100, pages 2070 - 2075
    - PETERSON et al., Cancer Res., (19960000), vol. 56, pages 3980 - 3985
    - OMELYANENKO et al., Int. J. Cancer, (19980000), vol. 75, pages 600 - 608
    - AMORINO et al., Radiat. Oncol. Investig., (19990000), vol. 7, pages 343 - 352
    - CHOY, Oncology, (19990000), vol. 13, pages 22 - 38
    - SAFRAN et al., Cancer Invest., (20010000), vol. 19, pages 1 - 7
    - DIONET et al., Anticancer Res., (20020000), vol. 22, pages 721 - 725
    - CIVIDALLI et al., Radiat. Oncol. Biol. Phys., (20020000), vol. 52, pages 1092 - 1098
    - CHOY, Oncology, (20000000), vol. 14, pages 7 - 14
    - MORNEXGIRARD, Annals of Oncology, (20060000), vol. 17, pages 1743 - 1747
    - INANAMI et al., Int. J. Radiat. Biol., (20020000), vol. 78, pages 267 - 274
    - TAMULEVICIUS et al., Br. J. Radiology, (19810000), vol. 54, pages 318 - 324
    - PALCIC et al., Radiat. Res., (19840000), vol. 100, pages 340 - 347
    - MASUNAGA et al., Br. J. Radiol., (20060000), vol. 79, pages 991 - 998
    - RISCHIN et al., J. Clin. Oncol., (20010000), vol. 19, pages 535 - 542
    - SHULMAN et al., Int. J. Radiat. Oncol. Biol. Phys., (19990000), vol. 44, pages 349 - 353
    - BUCHHOLZ et al., Int. J. Radiat. Oncol. Biol. Phys., (19950000), vol. 32, pages 1053 - 1058
    - SOGAARD et al., "Antibody-targeted superantigens in cancer immunotherapy", Immunotechnology, (19960000), vol. 2, no. 3, doi:10.1016/S1380-2933(96)00047-4, pages 151 - 162, XP002956583

DOI:   http://dx.doi.org/10.1016/S1380-2933(96)00047-4
    - GIANTONIO et al., J. Clin. Oncol., (19970000), vol. 15, pages 1994 - 2007
    - CHENG et al., J. Clin. Oncol., (20040000), vol. 22, pages 602 - 609
    - TERMAN et al., Clin. Chest Med., (20060000), vol. 27, pages 321 - 324
    - PERABO et al., Int. J. Cancer, (20050000), vol. 115, pages 591 - 598
    - BAGSHAWE et al., Current Opinions in Immunology, (19990000), vol. 11, pages 579 - 583
    - WILMAN, "Prodrugs in Cancer Therapy", Biochemical Society Transactions, (19860000), vol. 14, pages 375 - 382
    - "Prodrugs: A Chemical Approach To Targeted Drug Delivery", STELLA et al., Directed Drug Delivery, Humana Press, (19850000), pages 247 - 267
    - ROOSEBOOM et al., Pharmacol. Reviews, (20040000), vol. 56, pages 53 - 102
    - OZERS et al., "The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay", Biochemistry, (20070000), vol. 46, page 683
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.